ArticleFrontiers in oncology2024

Prognosis in HR-positive metastatic breast cancer with HER2-low versus HER2-zero treated with CDK4/6 inhibitor and endocrine therapy: a meta-analysis.

Lin-Yu Xia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.